Heidelberg Pharma Financials
| HPHA Stock | EUR 2.38 0.03 1.24% |
Heidelberg |
Understanding current and past Heidelberg Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Heidelberg Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Heidelberg Pharma's assets may result in an increase in income on the income statement.
| Instrument | Germany Stock View All |
| Exchange | Hamburg Exchange |
| ISIN | DE000A11QVV0 |
| Benchmark | Dow Jones Industrial |
| Currency | EUR - Euro |
You should never invest in Heidelberg Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Heidelberg Stock, because this is throwing your money away. Analyzing the key information contained in Heidelberg Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Heidelberg Pharma Key Financial Ratios
There are many critical financial ratios that Heidelberg Pharma's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Heidelberg Pharma reports annually and quarterly.Heidelberg Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Heidelberg Pharma's current stock value. Our valuation model uses many indicators to compare Heidelberg Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Heidelberg Pharma competition to find correlations between indicators driving Heidelberg Pharma's intrinsic value. More Info.Heidelberg Pharma AG is rated below average in current valuation category among its peers. It is one of the top stocks in price to book category among its peers . The ratio of Current Valuation to Price To Book for Heidelberg Pharma AG is about 7,853,241 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Heidelberg Pharma's earnings, one of the primary drivers of an investment's value.Heidelberg Pharma Systematic Risk
Heidelberg Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Heidelberg Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Heidelberg Pharma correlated with the market. If Beta is less than 0 Heidelberg Pharma generally moves in the opposite direction as compared to the market. If Heidelberg Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Heidelberg Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Heidelberg Pharma is generally in the same direction as the market. If Beta > 1 Heidelberg Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Heidelberg Pharma January 6, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Heidelberg Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Heidelberg Pharma AG. We use our internally-developed statistical techniques to arrive at the intrinsic value of Heidelberg Pharma AG based on widely used predictive technical indicators. In general, we focus on analyzing Heidelberg Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Heidelberg Pharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.61 | |||
| Information Ratio | 0.0347 | |||
| Maximum Drawdown | 19.68 | |||
| Value At Risk | (4.64) | |||
| Potential Upside | 5.26 |
Other Information on Investing in Heidelberg Stock
Heidelberg Pharma financial ratios help investors to determine whether Heidelberg Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Heidelberg with respect to the benefits of owning Heidelberg Pharma security.